

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5101382

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RAJASHREE JOSHI-HANGAL	08/15/2018
NIPUN DAVAR	08/15/2018
STEPHEN R. PRIEBE	08/15/2018
RECEIVING PARTY DATA	
Name:	ASTEX PHARMACEUTICALS, INC.
Street Address:	4420 ROSEWOOD DRIVE
City:	PLEASANTON
State/Country:	CALIFORNIA
Postal Code:	94588
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16053354
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	rgallo@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1050
ATTORNEY DOCKET NUMBER:	12636-370.201
NAME OF SUBMITTER:	TRISHA AGRAWAL
SIGNATURE:	/Trisha Agrawal/
DATE SIGNED:	08/21/2018
Total Attachments: 4	
source=Astex_12636_370_201_AssignmenttoOtsuka#page1.tif	
source=Astex_12636_370_201_AssignmenttoOtsuka#page2.tif	
source=Astex_12636_370_201_AssignmenttoOtsuka#page3.tif	
source=Astex_12636_370_201_AssignmenttoOtsuka#page4.tif	

ASSIGNMENT AGREEMENT

AGREEMENT by and between:

Rajashree JOSHI-HANGAL, a citizen of the United States, residing at
1070 W Lagoon Rd., Pleasanton, CA 94566, USA;

Nipun DAVAR, a citizen of the United States, residing at
868 Piemonte Dr., Pleasanton, CA 94566, USA; and

Stephen R. PRIEBE, a citizen of the United States, residing at
5218 Owens Dr., Apt 303, Pleasanton, CA 94588, USA.

the foregoing parties alternatively and collectively denominated herein as the INVENTORS;
and

Astex Pharmaceuticals, Inc., having offices at 4420 Rosewood Drive, Suite 200,
Pleasanton, CA, 94588,

all of the above parties denominated herein individually and collectively as ASSIGNORS; and

Otsuka Pharmaceutical Co., Ltd., a Japanese corporation, with an office at
2-9 Kanda Tsukasa-machi, Chiyoda-ku, Tokyo, Japan,

denominated herein as ASSIGNEE;

WITNESSETH:

WHEREAS, the INVENTORS have invented certain new and useful improvements in

DRUG COMPOUND AND PURIFICATION METHODS THEREOF

for which a Non Provisional Application for Letters Patents in the United States was filed on **August 2, 2018** and was accorded U.S. Serial No.16/053,354 (the "U.S. Non Provisional Application"); and

WHEREAS, ASSIGNOR **Astex Pharmaceuticals, Inc.** holds certain right, title and interest in, to and under said improvements and the said U.S. Non Provisional Application through its employment of INVENTORS **Rajashree JOSHI-HANGAL, Nipun DAVAR, and Stephen R. PRIEBE;** and

WHEREAS, INVENTORS **Rajashree JOSHI-HANGAL, Nipun DAVAR, and Stephen R. PRIEBE** desire, by this document, to confirm the ownership of their entire right, title and interest

in, to and under said improvements and the said U.S. Non Provisional Application by ASSIGNOR **Astex Pharmaceuticals, Inc.**; and

WHEREAS, ASSIGNEE **Otsuka Pharmaceutical Co., Ltd.** is desirous of obtaining the entire right, title and interest in, to and under the said improvements and the said U.S. Non Provisional Application, as held by all ASSIGNORS herein; and

WHEREAS all ASSIGNORS are desirous of vesting said entire right, title and interest in, to and under the said improvements and the said U.S. Non Provisional Application to ASSIGNEE.

NOW, THEREFORE, for other good and valuable consideration, the receipt of which is hereby acknowledged,

(i) the said

Rajashree JOSHI-HANGAL, Nipun DAVAR and Stephen R. PRIEBE

confirm that we have assigned, transferred and set over, and to the extent not already done so, by these presents do hereby assign, transfer and set over, to the said

Astex Pharmaceuticals, Inc.,

its successors, legal representatives and assigns, our entire right, title and interest in, to and under the said improvements, and the said U.S. Non Provisional Application and all divisions, renewals, and continuations thereof and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said improvements in any country or countries foreign to the United States, including the right to claim priority under the terms of any appropriate International Convention based upon said application for Letters Patent of the United States, and all Letters Patent which may be granted from said improvements in any country or countries foreign to the United States and extensions, renewals and reissues thereof, and including the right to sue for past infringement; and we hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States, whose duty is to issue patents on applications as aforesaid, to issue all Letters Patent for said improvements to the said

Astex Pharmaceuticals, Inc.,

its successors, legal representatives and assigns, in accordance with the terms of this assignment agreement; and

(ii) the said

Astex Pharmaceuticals, Inc.,

confirm that we have assigned, transferred and set over, and to the extent not already done so by these presents do hereby assign, transfer and set over, to the said

Otsuka Pharmaceutical Co., Ltd.,

its successors, legal representatives and assigns, our entire right, title and interest in, to and under the said improvements, and the said U.S. Non Provisional Application and all divisions, renewals, and continuations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said improvements in any country or countries foreign to the United States, including the right to claim priority under the terms of any appropriate International Convention based upon said application for Letters Patent of the United States, and all Letters Patent which may be granted from said improvements in any country or countries foreign to the United States and extensions, renewals and reissues thereof, and including the right to sue for past infringement; and we hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States, whose duty is to issue patents on applications as aforesaid, to issue all Letters Patent for said improvements to the said

Otsuka Pharmaceutical Co., Ltd.,

its successors, legal representatives and assigns, in accordance with the terms of this assignment agreement.

AND THE INVENTORS HEREBY further covenant and agree that we will, upon reasonable request of said

Otsuka Pharmaceutical Co., Ltd.,

communicate to the said

Otsuka Pharmaceutical Co., Ltd.,

its successors, legal representatives and assigns, any fact known to us respecting said improvements, and testify in any legal proceeding, sign all lawful papers, execute all divisions, continuing and reissue applications, make all rightful oaths and generally do everything reasonable to aid the said

Otsuka Pharmaceutical Co., Ltd.,

its successors, legal representatives and assigns, to obtain and enforce proper protection under patent laws for said improvements in the United States and in any country or countries foreign to the United States.

IN TESTIMONY WHEREOF, the said **Rajashree JOSHI-HANGAL**, **Nipun DAVAR**, and **Stephen R. PRIEBE**, **Astex Pharmaceuticals, Inc.**, and **Otsuka Pharmaceutical Co., Ltd.** have executed this assignment agreement on the date opposite each signature.

This assignment agreement may be executed in counterparts.

Rajashree
Rajashree JOSHI-HANGAL

Date: 15 AUG 2018

Nipun
Nipun DAVAR

Date: 15 AUG 2018

Stephen R. Priebe
Stephen R. PRIEBE

Date: 15 Aug 2018

Astex Pharmaceuticals, Inc.

Date: AUGUST 15TH, 2018

Martin Buckland

By: Martin Buckland

Title: Chief Corporate Officer

Otsuka Pharmaceutical Co., Ltd.

Date: 17 August 2018

Otsu Nagai

By: Nagai Osamu

Title: Director of Intellectual Property